AKT1 and cancer: Investigating the inhibition of MAPK and PI3K/AKT pathways can lead to an improved understanding of cancer progression and survival, as well as of the cross talk between the two pathways, which will be critical for the development of therapies that bypass the causes that lead to the development of drug resistance.